BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
1. BioCryst to acquire ATXS for $13 per share, valued at $700 million. 2. Deal includes cash and stock, with $8.55 cash per ATXS share. 3. ATXS's Navenibart enhances BioCryst's portfolio in hereditary angioedema treatment. 4. Transaction expected to close in Q1 2026, enabling future profitability. 5. Astria shareholders to own 15% of combined entity post-acquisition.